Cara Therapeutics reported $32.7M in Operating Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Acadia Pharmaceuticals ACAD:US $ 228.48M 53.07M
Acelrx Pharmaceuticals ACRX:US $ 9.44M 1.26M
Aerie Pharmaceuticals AERI:US $ 63.48M 552K
Cara Therapeutics CARA:US $ 32.7M 1.64M
Chugai Pharma 4519:JP 173.55B 9.66B
Depomed DEPO:US $ 24.98M 368K
Endo International Ordinary Shares ENDP:US $ 583.27M 618.52M
Halozyme Therapeutics HALO:US $ 41.61M 3.86M
Horizon Pharma HZNP:US $ 690.93M 90.45M
JAZZ PHA JAZZ:US $ 726.17M 121.18M
Pacira Pharmaceuticals PCRX:US $ 140.6M 14.38M
Pain Therapeutics PTIE:US $ 17.82M 3.38M
Revance Therapeutics RVNC:US $ 87.48M 72K
Supernus Pharmaceuticals SUPN:US $ 150.54M 2.41M
Teva Pharmaceutical Industries TEVA:US 4.37B 352M
Vanda Pharmaceuticals VNDA:US $ 67.86M 8.48M